Echocardiographic changes on GLP-1 — anyone have experience?

Dr.RaviCardio said:

Dr.LipidDallas said: ...cardiovascular risk is just another fad...

NNT calculation for cardiovascular risk clinical endpoints: NNT = 1/ARR (absolute risk reduction).

From SELECT trial: MACE at 39 months — 6.5% semaglutide vs 8.0% placebo. ARR = 1.5%. NNT = 67 over 3.3 years.

Compare to established therapies:

These NNTs are clinically meaningful and comparable to accepted cardiovascular interventions.

LipidDoc_ATL said:

SUSTAIN-6 was the first CVOT to show cardiovascular benefit with semaglutide, relevant to cardiovascular risk.

Thank you for spelling out the reasoning rather than just the conclusion.

Dr.RaviCardio said:

Dr.LipidDallas said: ...cardiovascular risk is just another fad...

Mendelian randomization evidence supporting GLP-1 pathway modulation for cardiovascular risk: genetic variants in the GLP1R gene region associated with lower BMI also show associations with reduced cardiovascular risk, confirming a causal pathway[1].

This "natural experiment" (people born with genetically higher GLP-1 signaling being leaner and healthier) provides orthogonal evidence supporting the pharmacological approach. When genetic epidemiology, clinical trials, and mechanistic studies all converge, confidence in the therapeutic approach is high.

pete_manc_UK said:

My reason for being on this is cardiovascular rather than cosmetic, which puts me in a small minority in most of these threads.

Cardiac biomarkers and cardiovascular risk: my cardiologist ordered advanced cardiac labs given my family history. Results were encouraging:

• NT-proBNP: 65 pg/mL (normal, cardiac function preserved)
• Lp(a): 45 nmol/L (genetic, unchanged — expected)
• ApoB: dropped from 155 to 90 mg/dL (excellent response)
• Coronary calcium score: 0 (unchanged from baseline — reassuring)

The ApoB reduction is particularly meaningful — it's considered the best single predictor of cardiovascular risk. GLP-1 therapy seems to improve this consistently.

Moderator note: a post naming a supplier has been edited. Discuss suppliers in the review sections, not here. Carry on.